Literature DB >> 20547105

MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.

Swagatam Ray1, Arvind Chhabra, Nitya G Chakraborty, Upendra Hegde, David I Dorsky, Thinle Chodon, Erika von Euw, Begonya Comin-Anduix, Richard C Koya, Antoni Ribas, James S Economou, Steven A Rosenberg, Bijay Mukherji.   

Abstract

MHC class I-restricted human melanoma epitope MART-1(27-35) specific TCR-engineered CD4+CD25- T cells synthesize Th1 type cytokines and exhibit cytolytic effector function upon cognate stimulation. A detailed characterization of such TCR-engineered CD4+CD25- T cells now reveals that they are multifunctional. For example, they undergo multiple rounds of division, synthesize cytokines (IFN-gamma, TNF-alpha, IL-2, and MIP1ss), lyse target cells, and "help" the expansion of the MART-1(27-35) specific CD8+ T cells when stimulated by the MART-1(27-35) peptide pulsed DC. Multiparametric analyses reveal that a single TCR-engineered CD4+ T cell can perform as many as five different functions. Nearly 100% MART-1(27-35) specific TCR expressing CD4+ T cells can be generated through retroviral vector-based transduction and one round of in vitro stimulation by the peptide pulsed DC. MHC class I-restricted tumor epitope specific TCR transduced CD4+ T cells, therefore, could be useful in immunotherapeutic strategies for melanoma or other human malignancies. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20547105      PMCID: PMC2917536          DOI: 10.1016/j.clim.2010.04.013

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  33 in total

Review 1.  Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution.

Authors:  A B Lyons
Journal:  J Immunol Methods       Date:  2000-09-21       Impact factor: 2.303

2.  CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes.

Authors:  Edith M Janssen; Edward E Lemmens; Tom Wolfe; Urs Christen; Matthias G von Herrath; Stephen P Schoenberger
Journal:  Nature       Date:  2003-02-09       Impact factor: 49.962

3.  Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro.

Authors:  Shikhar Mehrotra; Robert Stevens; Ryan Zengou; Nitya G Chakraborty; Lisa H Butterfield; James S Economou; David I Dorsky; Bijay Mukherji
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

4.  Generation of T cell help through a MHC class I-restricted TCR.

Authors:  Helmut W H G Kessels; Koen Schepers; Marly D van den Boom; David J Topham; Ton N M Schumacher
Journal:  J Immunol       Date:  2006-07-15       Impact factor: 5.422

5.  CD8 alpha coreceptor to improve TCR gene transfer to treat melanoma: down-regulation of tumor-specific production of IL-4, IL-5, and IL-10.

Authors:  Ralph A Willemsen; Zsolt Sebestyén; Cees Ronteltap; Cor Berrevoets; Joost Drexhage; Reno Debets
Journal:  J Immunol       Date:  2006-07-15       Impact factor: 5.422

6.  A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection.

Authors:  Emma C Morris; Aristotle Tsallios; Gavin M Bendle; Shao-An Xue; Hans J Stauss
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-20       Impact factor: 11.205

Review 7.  CD4+ T lymphocytes: a critical component of antitumor immunity.

Authors:  Suzanne Ostrand-Rosenberg
Journal:  Cancer Invest       Date:  2005       Impact factor: 2.176

8.  Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.

Authors:  Ying Xie; Akgül Akpinarli; Charles Maris; Edward L Hipkiss; Malcolm Lane; Eun-Kyung M Kwon; Pawel Muranski; Nicholas P Restifo; Paul Andrew Antony
Journal:  J Exp Med       Date:  2010-02-15       Impact factor: 14.307

Review 9.  T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?

Authors:  Michael Campoli; Soldano Ferrone
Journal:  Expert Rev Vaccines       Date:  2004-04       Impact factor: 5.217

10.  High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.

Authors:  Richard A Morgan; Mark E Dudley; Yik Y L Yu; Zhili Zheng; Paul F Robbins; Marc R Theoret; John R Wunderlich; Marybeth S Hughes; Nicholas P Restifo; Steven A Rosenberg
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

View more
  20 in total

1.  Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope.

Authors:  Hsueh-Ling Janice Oh; Adeline Chia; Cynthia Xin Lei Chang; Hoe Nam Leong; Khoon Lin Ling; Gijsbert M Grotenbreg; Adam J Gehring; Yee Joo Tan; Antonio Bertoletti
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

2.  Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells.

Authors:  Timothy T Spear; Yuan Wang; Kendra C Foley; David C Murray; Gina M Scurti; Patricia E Simms; Elizabeth Garrett-Mayer; Lance M Hellman; Brian M Baker; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2017-06-20       Impact factor: 6.968

3.  TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms.

Authors:  Oleg Y Borbulevych; Sujatha M Santhanagopolan; Moushumi Hossain; Brian M Baker
Journal:  J Immunol       Date:  2011-07-27       Impact factor: 5.422

4.  Knockdown of T-bet expression in Mart-127-35 -specific T-cell-receptor-engineered human CD4(+)  CD25(-) and CD8(+) T cells attenuates effector function.

Authors:  Sidharth S Jha; Nitya G Chakraborty; Prashant Singh; Bijay Mukherji; David I Dorsky
Journal:  Immunology       Date:  2015-05       Impact factor: 7.397

Review 5.  Strategies to genetically engineer T cells for cancer immunotherapy.

Authors:  Timothy T Spear; Kaoru Nagato; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-05-02       Impact factor: 6.968

Review 6.  PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab.

Authors:  Ali R Jazirehi; Alexandra Lim; Tam Dinh
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

7.  Death receptor-independent activation-induced cell death in human melanoma antigen-specific MHC class I-restricted TCR-engineered CD4 T cells.

Authors:  Arvind Chhabra; Bijay Mukherji
Journal:  J Immunol       Date:  2013-08-09       Impact factor: 5.422

Review 8.  Trial Watch: Adoptive cell transfer for oncological indications.

Authors:  Fernando Aranda; Aitziber Buqué; Norma Bloy; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-05-05       Impact factor: 8.110

Review 9.  T-cell receptor gene therapy--ready to go viral?

Authors:  Terhi Karpanen; Johanna Olweus
Journal:  Mol Oncol       Date:  2015-10-20       Impact factor: 6.603

10.  Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo.

Authors:  Ingunn M Stromnes; Carla Fowler; Chanel C Casamina; Christina M Georgopolos; Megan S McAfee; Thomas M Schmitt; Xiaoxia Tan; Tae-Don Kim; Inpyo Choi; Joseph N Blattman; Philip D Greenberg
Journal:  J Immunol       Date:  2012-07-13       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.